Friday, June 13, 2025

Latest

PharmaTher Secures Japanese Patent For Ketabet

PharmaTher Holdings (CSE: PHRM) announced today that it has been granted a Japanese patent for its ketamine combination formulation, Ketabet. The patent is expected to cover the application until 2036.

“We are extremely pleased about the grant of this patent by the Japanese Patent Office as it validates the novelty and potential of KETABET™ for unmet medical needs,” stated PharmaTher CEO Fabio Chianelli. “[This] increases our ability to enter into potential new commercial partnerships for KETABET™ in Japan and major international markets.”

Ketabet is a combination formulation of FDA-approved ketamine and betaine anhydrous. Research has shown its capability to enhance the antidepressant effect while reducing the known negative side effects of ketamine.

The firm has also a granted patent in Taiwan and current patent applications in the US, Europe, Canada, Israel, and China.

PharmaTher Holdings last traded at $0.40 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. PharmaTher Holdings is a former client of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Aznalcóllar Corruption Case Nears Conclusion | David Gower – Emerita Resources

Why Precious Metals Crashed on Trump’s Trade Deals? | Jesse Day

Big Gold Miners Don’t Trust $3,300 Gold, Do They See a Crash Ahead? | Rob McEwen

Recommended

NexGen Energy Receives Approval For Site Expansion At Rook I Project

ESGold Sees Installation Of Humphrey Spirals Completed At Montauban

Related News

Pharmather Acquires Exclusive License For Ketamine Treatment Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) this morning announced that it has entered into an exclusive licensing...

Thursday, October 15, 2020, 09:02:27 AM

PharmaDrug JV Submits Application For Phase 1 Clinical Trials In Australia

PharmaDrug Inc (CSE: DRUG) has seen one of its joint ventures advance to the clinical...
Wednesday, May 15, 2024, 09:17:48 AM

PharmaTher Collaborates For Research On Psychedelic Microdosing Tech

PharmaTher Inc (CSE: PHRM) this morning announced that it will be conducting further research related...

Tuesday, February 23, 2021, 07:25:33 AM

PharmaTher Receives FDA Approval For Ketamine Trial For Parkinson’s

PharmaTher Holdings (CSE: PHRM) has seen the US FDA approve the firms application for an...

Monday, May 17, 2021, 09:15:31 AM

PharmaTher Partners With TSRL For Microneedle Patch Development

PharmaTher Holdings (CSE: PHRM) has partnered with that of TSRL under a co-development agreement. The...

Tuesday, June 1, 2021, 08:21:51 AM